Scalper1 News
Gilead Sciences late Tuesday blew past Q1 revenue and earnings forecasts as sales of its new hepatitis C drug Sovaldi far exceeded expectations, but fellow big biotech Amgen missed expectations. Gilead (GILD) stock was up 2.5% after hours, after its Q1 report included sales of $2.27 billion for the expensive Sovaldi, which it started selling in December. Analyst sales estimates ranged from near $1 billion to $2 billion. “We believe expectations Scalper1 News
Scalper1 News